- Home
- ARQT vs VTEX Comparison
ARQT vs VTEX Comparison
Compare ARQT & VTEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- VTEX
- Stock Information
- Founded
- ARQT 2016
- VTEX 1999
- Country
- ARQT United States
- VTEX United Kingdom
- Employees
- ARQT N/A
- VTEX N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- VTEX Computer Software: Prepackaged Software
- Sector
- ARQT Health Care
- VTEX Technology
- Exchange
- ARQT Nasdaq
- VTEX Nasdaq
- Market Cap
- ARQT 1.1B
- VTEX 1.2B
- IPO Year
- ARQT 2020
- VTEX 2021
- Fundamental
- Price
- ARQT $13.08
- VTEX $6.58
- Analyst Decision
- ARQT Strong Buy
- VTEX Buy
- Analyst Count
- ARQT 5
- VTEX 4
- Target Price
- ARQT $17.00
- VTEX $9.75
- AVG Volume (30 Days)
- ARQT 1.9M
- VTEX 648.2K
- Earning Date
- ARQT 02-25-2025
- VTEX 02-25-2025
- Dividend Yield
- ARQT N/A
- VTEX N/A
- EPS Growth
- ARQT N/A
- VTEX N/A
- EPS
- ARQT N/A
- VTEX 0.05
- Revenue
- ARQT $138,708,000.00
- VTEX $225,906,000.00
- Revenue This Year
- ARQT $215.24
- VTEX $17.10
- Revenue Next Year
- ARQT $53.63
- VTEX $17.73
- P/E Ratio
- ARQT N/A
- VTEX $138.62
- Revenue Growth
- ARQT 182.84
- VTEX 21.27
- 52 Week Low
- ARQT $5.38
- VTEX $5.60
- 52 Week High
- ARQT $16.20
- VTEX $9.59
- Technical
- Relative Strength Index (RSI)
- ARQT 41.94
- VTEX 59.51
- Support Level
- ARQT $13.33
- VTEX $6.46
- Resistance Level
- ARQT $15.09
- VTEX $6.93
- Average True Range (ATR)
- ARQT 0.86
- VTEX 0.23
- MACD
- ARQT -0.16
- VTEX 0.06
- Stochastic Oscillator
- ARQT 6.25
- VTEX 64.29
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About VTEX VTEX
Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.